在澳大利亚接受乙肝或丙肝病毒报告的人群中，肝细胞癌住

StephenW

Hepatol Commun. 2017 Aug 16;1(8):736-747. doi: 10.1002/hep4.1073. eCollection  2017 Oct.
Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014).Waziry R1, Grebely J1, Amin J2, Alavi M1, Hajarizadeh B1, George J3, Matthews GV1, Law M1, Dore GJ1.
Author information
1The Kirby InstituteUNSW SydneySydneyAustralia.2Faculty of Medicine and Health SciencesMacquarie UniversitySydneyAustralia.3Storr Liver UnitWestmead Millennium Institute and Westmead Hospital, University of SydneySydneyAustralia.

AbstractWe assessed trends in HCC survival in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection in New South Wales, Australia. Data on HBV (n = 54,399) and HCV (n = 96,908) notifications (1993-2012) were linked to a hospitalization database (July 2000-June 2014), the New South Wales Cancer Registry, and the New South Wales Death Registry. A total of 725 (1.3%) first HBV-hepatocellular carcinoma (HCC) and 1,309 (1.4%) first HCV-HCC hospitalizations were included. Death occurred in 60.4% of HBV-HCC and 69.6% of HCV-HCC patients. Median survival following first HBV-HCC hospitalization improved from 0.6 years (95% confidence interval [CI] 0.39-1.28) in 2000-2004 to 2.8 years (1.54-5.54) in 2010-2014. Median survival following first HCV-HCC hospitalization was 0.8 years (0.45-1.33) in 2000-2004 and 0.9 (0.67-1.18) in 2010-2014. One-year HBV-HCC survival in 2010-2014 compared to 2000-2004 improved for those with (94% versus 81%) and without (42% versus 33%) potentially curative procedures (liver resection, liver transplantation, and radiofrequency ablation). Factors associated with improved survival following HBV-HCC were later study period (hazard ratio [HR] = 0.74; 95% CI, 0.57-0.97) and potentially curative procedures (liver resection, liver transplantation, and radiofrequency ablation) (HR = 0.23; 95% CI, 0.17-0.29), while male gender (HR = 1.37; 95% CI, 1.03-1.82), human immunodeficiency virus coinfection (HR = 3.06; 95% CI, 1.36-6.88), and Charlson Comorbidity Index ≥3 (HR = 1.81; 95% CI, 1.35-2.40) were associated with reduced survival. Factors associated with improved survival following HCC-HCV were Asia-Pacific country of birth (HR = 0.68; 95% CI, 0.55-0.84) and potentially curative procedures (HR = 0.21; 95% CI, 0.17-0.25), while age (HR = 1.01; 95% CI, 1.01-1.02), rural place of residence (HR = 1.46; 95% CI, 1.22-1.74), and human immunodeficiency virus coinfection (HR = 2.71; 95% CI, 1.19-6.15) were associated with reduced survival. Conclusion: All-cause survival following HBV-HCC has improved considerably, suggesting an impact of more effective antiviral therapy and earlier HCC diagnosis; in contrast, all-cause survival for HCV-HCC is unchanged. (Hepatology Communications 2017;1:736-747).


PMID:29404490PMCID:PMC5678911DOI:10.1002/hep4.1073

StephenW

Hepatol Commun。 2017年8月16日; 1（8）：736-747。 doi：10.1002 / hep4.1073。 eCollection 2017年10月
在澳大利亚接受乙肝或丙肝病毒报告的人群中，肝细胞癌住院治疗后的生存率（2000-2014）。
Waziry R1，Grebely J1，Amin J2，Alavi M1，Hajarizadeh B1，George J3，Matthews GV1，Law M1，Dore GJ1。
作者信息

1
    Kirby学院UNSW SydneySydneyAustralia。
2
    医学和健康科学学院澳大利亚昆士兰大学澳大利亚。
3
    Storr Liver UnitWestmead千年研究所和悉尼大学Westmead医院澳大利亚。

抽象

我们评估了澳大利亚新南威尔士州乙型肝炎病毒（HBV）或丙型肝炎病毒（HCV）感染患者的HCC生存趋势。有关HBV（n = 54,399）和HCV（n = 96,908）通报（1993-2012）的数据与住院数据库（2000年7月至2014年6月），新南威尔士州癌症登记处和新南威尔士州死亡登记处相关。首先包括725（1.3％）首次HBV-肝细胞癌（HCC）和1,309（1.4％）首次HCV-HCC住院。 HBV-HCC发生率为60.4％，HCV-HCC发生率为69.6％。首次HBV-HCC住院治疗后的中位生存期从2000 - 2004年的0.6年（95％置信区间[CI] 0.39-1.28）提高到2010 - 2014年的2.8年（1.54-5.54）。首次HCV-HCC住院后的中位生存期为2000 - 2004年0.8年（0.45-1.33），2010 - 2014年为0.9（0.67-1.18）。对于那些（94％比81％）和没有（42％比33％）潜在治愈性手术（肝切除，肝移植和射频消融）的患者，2010 - 2014年一年的HBV-HCC生存率与2000 - 。 （HR = 0.74; 95％CI，0.57〜0.97）和可能的治疗方法（肝切除，肝移植和射频消融）（HR = 0.23;男性（HR = 1.37; 95％CI，1.03-1.82），人类免疫缺陷病毒共感染（HR = 3.06; 95％CI，1.36-6.88）和Charlson合并症指数≥3（95％CI，0.17-0.29） （HR = 1.81; 95％CI，1.35-2.40）与生存率降低有关。与HCC-HCV改善生存率相关的因素是亚太地区出生（HR = 0.68; 95％CI，0.55-0.84）和潜在的治愈程序（HR = 0.21; 95％CI，0.17-0.25），而年龄HR = 1.01; 95％CI，1.01-1.02），农村居住地（HR = 1.46; 95％CI，1.22-1.74）和人类免疫缺陷病毒共感染（HR = 2.71; 95％CI，1.19-6.15）与生存率降低有关。结论：HBV-HCC的全因死亡率有显着改善，提示更有效的抗病毒治疗和HCC早期诊断的影响;相比之下，HCV-HCC的全因存活不变。 （Hepatology Communications 2017; 1：736-747）。

结论：
    29404490
PMCID：
    PMC5678911
DOI：
    10.1002 / hep4.1073

9病成医